Ipsen and Marengo Therapeutics expand their oncology research partnership, incorporating TriSTAR, Marengo's next-gen precision T cell engager technology.
Ipsen and Marengo Therapeutics expand their ongoing oncology research partnership, incorporating TriSTAR, Marengo's next-generation precision T cell engager (TCE) technology. Traditional TCEs have limited efficacy due to poor T cell quality and exhaustion, but Marengo's proprietary TriSTAR TCEs have the potential to overcome these limitations. This marks the companies' second strategic partnership.
June 07, 2024
3 Articles